Boehringer Ingelheim GmbH Logo
2016-03-08 18:00
New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma - Regardless of Allergy Subtype[1,2,3]
  • SPIRIVA® Respimat® shown effective in the broad range of asthma patients studied who continued to experience symptoms despite taking other asthma maintenance therapies[4]
    New analyses show improved lung function* and asthma symptom control and reduced asthma exacerbations for patients with allergic asthma[1,2,3]
INGELHEIM, GERMANY--(Business Wire/Korea Newswire) March 8, 2016 -- Boehringer Ingelheim today announced the presentation of new post-hoc analyses that show the addition of SPIRIVA® (tiotropium) Respimat® to other asthma maintenance therapies helps improve lung function and asthma symptom control, while reducing asthma exacerbations (also known as flare-ups), independent of a patient’s subtype of allergic asthma.[1,2,3] These data were presented at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Los Angeles.

These analyses evaluated the safety and efficacy of adding SPIRIVA® Respimat® to other maintenance therapies compared to placebo across the broad range of asthma patients studied, regardless of the allergic (Immunoglobulin E or IgE) and inflammatory (eosinophilic) levels.

The addition of SPIRIVA® Respimat® significantly improved lung function.*3 Adding SPIRIVA® Respimat® also was shown to improve asthma symptom control, as measured by the seven question Asthma Control Questionnaire (ACQ-7)[2] and reduce the risk of asthma worsening and exacerbations.[1]

“The data confirm that adding SPIRIVA® Respimat® is a well-tolerated and effective treatment option for asthma patients independent of allergic subtype,” said Mark Vandewalker, MD, director, Clinical Research of the Ozarks, Columbia, Missouri. “For people with allergic asthma who are still experiencing symptoms, adding SPIRIVA® Respimat® may help open airways to improve breathing.”

People living with allergic asthma - the most common form of the condition - experience inflammation and a tightening of the airways due to exposure to common allergens. These patients may need other inhaled options that complement their existing therapy.

SPIRIVA® Respimat® is the first new class of inhaled medicine approved in over 10 years for asthma.[5] It complements a patient’s other maintenance therapies (usually ICS/LABA) to reduce asthma symptoms and the risk of asthma flare-ups. SPIRIVA® Respimat® in asthma is delivered by Respimat®, the inhaler which actively† delivers a unique mist,[6] meaning the patient just needs to take a deep breath in[7] for the medication to go deep into the lungs.[8,9,10]

“Boehringer Ingelheim is committed to pursuing scientific research to help address unmet needs and improve patient care for people living with asthma,” said William Mezzanotte, Head of Respiratory Medicine, Boehringer Ingelheim. “These data further demonstrate the benefits of SPIRIVA® Respimat® for the broad range of asthma patients studied who continued to experience symptoms despite taking other maintenance therapies, regardless of allergy subtype.”

The post-hoc analyses are based on data from the two PrimoTinA-asthma® and two MezzoTinA-asthma® trials which are part of the UniTinA-asthma® large-scale clinical trial programme:

· The PrimoTinA-asthma® trials investigated SPIRIVA® Respimat® as an add-on therapy for adults with asthma who continued to have symptoms despite taking at least ICS/LABA therapy.

· The MezzoTinA-asthma® trials investigated SPIRIVA® Respimat® as an add-on therapy for adults with asthma who continued to have symptoms despite taking at least moderate-dose ICS therapy.

The safety and tolerability of SPIRIVA® Respimat® in each trial and treatment group were comparable with those of placebo in the overall patient population.[4,11]

For more information please visit www.boehringer-ingelheim-congress.com and www.respimat.com

For more information on SPIRIVA® RESPIMAT® and asthma, please visit Boehringer Ingelheim News Centre (http://goo.gl/2DBDRz).

For references and notes to editors please visit http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2016/08_march_2016_asthma.html

* As measured by peak forced expiratory volume (volume of air that can be forced out after taking a deep breath) in one second (FEV1) and trough FEV1

† Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

View source version on businesswire.com: http://www.businesswire.com/news/home/20160308005699/en/
Boehringer Ingelheim GmbH 전체 보도자료 보기
이 뉴스는 기업·기관이 발표한 보도자료 전문입니다. 언론 매체와 블로그는 보도를 목적으로 이 보도자료를 사용할 수 있습니다. 보도자료 등록 안내
Media Contact

Boehringer Ingelheim
Katharina Opitz
Phone: +49 6132 - 77 2012
Fax: +49 6132 - 77 6601
press@boehringer-ingelheim.com

이 보도자료 관련 분야

건강  제약  개발  해외

관심 분야 보도자료 구독 방법

가입하면 관심 분야 보도자료를 마이 뉴스와 이메일로 볼 수 있습니다. 스마트폰과 RSS로도 가능합니다.

보도자료 배포 서비스 안내

뉴스와이어는 4천여개 언론매체에서 일하는 1만7천여명의 기자에 보도자료를 배포해 언론이 보도할 수 있게 합니다.

해외 보도자료 배포 안내
비즈니스와이어와 제휴해 해외 언론에 보도자료를 배포합니다.